Using pre-treatment APM expression data, the APM model predicted tumors (C1) that could simultaneously upregulate APM expression and anti-tumor immune infiltration following treatment, which shaped the sensitivity to ICB. The gene discussed is ANPEP; the disease is neoplasm.